OncoMatch/Clinical Trials/NCT03067051
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
Is NCT03067051 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Verteporfin and SpectraCure P18 System for recurrent prostate cancer.
Treatment: Verteporfin · SpectraCure P18 System — The rationale for the study is to obtain safety and efficacy data as well as to establish dose parameters for the SpectraCure P18 System with IDOSE®, with verteporfin for injection (VFI) as photosensitizer for the treatment of recurrent prostate cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: external or internal, high dose rate (brachy) radiation therapy — localized prostate cancer
have gone through external or internal, high dose rate (brachy) radiation therapy for localized prostate cancer with histopathologically verified local recurrence
Cannot have received: seed implantation brachytherapy
Patients who have been treated with seed implantation brachytherapy
Lab requirements
Blood counts
granulocyte count ≥ 1500/mm3, platelet count ≥ 100,000/mm3
Kidney function
creatinine ≤ 1.5 mg/dl
Liver function
total bilirubin ≤ 1.5 mg/dl, sgot ≤ 3x uln, alt ≤ 3x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Cancer Center · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03067051 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior seed implantation brachytherapy disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages